Ubenimex

TOKUSHIMA, Japan--(BUSINESS WIRE)-- We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival (mPFS; 23.1 months). Subsequently, based on these results, we have been in negotiation with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan with the aim of submitting a conditional approval application, resulting in our decision to conduct a Phase III clinical trial (superiority study) of DFP-14323 in combination with afatinib (20 mg/day) versus afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer patients with uncommon EGFR mutation positive based on the PMDA's recommendation. And finally, we are pleased to announce that the submission of the protocol for the Phase III study to the PMDA has been approved and are ready to initiate the study. This Phase III clinical trial will be conducted at 30 sites in Japan and if the superiority of the add-on effect of DFP-14323 on progression-free survival (PFS) as primary endpoint, is confirmed in this trial, we believe that DFP-14323 will be a novel cancer immunotherapy drug with highly beneficial for patients and their families, as it is orally available, safe, and economical. Furthermore, if non-inferiority to osimertinib (80 mg/day) can be confirmed in a comparative study, a huger market can be expected. We intend to continue negotiations for out-licensing opportunities with pharmaceutical companies for the territory outside Japan. Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. (TOKYO:4598) and contact with us.

Lymphedema involves the accumulation of lymph fluid in fatty tissues just beneath the skin. The condition is caused due to impaired flow in the lymphatic system of a person and is observed either in the legs or arms or in both of them. It can also affect the abdomen, neck, genitals, and face of a person, depending on the portion of the body which has undergone treatment. Primary lymphedema is generally present at birth, while secondary lymphedema is caused due to dysfunction or damage to the lymphatic system. Cancer-related treatment is a prominent cause of secondary lymphedema. Surgery, radiation therapy, or cancer itself can hinder the flow of lymph fluid, leading to lymphedema. Symptoms of lymphedema include feeling of tightness or heaviness; swelling in the legs, arms, or other parts of the body; ache or discomfort; and fibrosis, which means thickening or hardening of the skin. Read Report Overview - Rise in the number of lymphedema cases globally is a prominent factor driving the growth of the global lymphedema treatment market. According to some estimates, 140-250 million people across the globe are affected by lymphedema. In the U.S., around 1-2 million people suffer from primary lymphedema, while 2-3 million are affected with secondary lymphedema. Rise in incidence of cancer, especially breast cancer, is another factor boosting the number of lymphedema cases globally. Patients undergoing radiation therapy or surgery for breast cancer treatment are at a high risk of developing lymphedema. Breast cancer is the most commonly observed cancer among women and is the second-most common type of cancer. According to the World Cancer Research Fund, an estimated 2 million cases of breast cancer were reported in 2018 across the world. Request Brochure of Report - Launch of new medical devices by companies is another factor contributing to the growth of the global lymphedema treatment market. In May 2017, Tactile Systems Technology, Inc., a prominent manufacturer of at-home therapy devices, announced the launch of Flexitouch system in the U.S. market. Flexitouch system is a pneumatic compression device for use in the treatment of lymphedma of neck and head. The device, which was granted approval by the U.S. Food and Drug Administration (FDA) in September 2016, is the only pneumatic compression system that can deliver non-invasive therapy to patients and can help in stimulating their lymphatic system. Ongoing research for the development of novel therapies for the treatment of lymphedema is another driver of the global lymphedema treatment market. According to a new study conducted at the Stanford University School of Medicine, a new molecular mechanism primarily responsible for causing lymphedema, along with a drug (bestatin) which has the potential for hindering the process, was uncovered in May 2017. Bestatin is currently undergoing clinical trials for the treatment of secondary lymphedema. Positive outcome from the trials is expected to be a step forward toward developing new treatment option for the management of lymphedema. Request for Analysis of COVID-19 Impact on Lymphedema Treatment Market - The global lymphedema treatment market can be segmented based on treatment type, end-user, and region. In terms of treatment type, the market can be classified into surgery, compression therapy, and others. Based on end-user, the lymphedema treatment market can be divided into hospitals, clinics, and others. In terms of geography, the global lymphedema treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global lymphedema treatment market due to launch of new products for the management of the condition. North America is followed by Europe and Asia Pacific in terms of dominance over the global lymphedema treatment market. In Asia Pacific, increasing incidence of breast cancer is likely to fuel the growth of the lymphedema treatment market during the forecast period. Pre Book Lymphedema Treatment Market Report at - Prominent players operating in the global lymphedema treatment market include Bio Compression Systems, Inc., BSN medical, Lohmann & Rauscher, Mego Afek ltd, SIGVARIS, and Tactile Systems Technology Inc. More Trending Reports by Transparency Market Research: Blood Pressure Cuffs Market: Hypertension is a global problem that continues to be one of the leading causes of premature death worldwide. The prevalence of hypertension is the highest in low to middle income countries in Africa and Asia Pacific, owing to lack of awareness related to the symptoms, long-term effects of the condition, and scarcity of healthcare facilities in these regions. Endosurgery Devices Market: Technological advancements have played an imperative role in transforming the modern day healthcare industry. Over the past decade, minimally invasive surgeries, also known as laparoscopy, have garnered significance, as they require smaller incisions. With additional efforts toward minimizing the size of surgical incisions, minimally invasive procedures are set to gain traction in the near future. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: